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offer a safer approach for targeting tau by
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The spread of tau pathology correlates with cognitive
decline in Alzheimer’s disease. In vitro, tau anti-
bodies can block cell-to-cell tau spreading. Although
mechanisms of anti-tau function in vivo are unknown,
effector function might promote microglia-mediated
clearance. In this study, we investigated whether
antibody effector function is required for targeting
tau. We compared efficacy in vivo and in vitro of
two versions of the same tau antibody, with and
without effector function, measuring tau pathology,
neuron health, and microglial function. Both anti-
bodies reduced accumulation of tau pathology in
Tau-P301L transgenic mice and protected cultured
neurons against extracellular tau-induced toxicity.
Only the full-effector antibody enhanced tau uptake
in cultured microglia, which promoted release of
proinflammatory cytokines. In neuron-microglia co-
cultures, only effectorless anti-tau protected neu-
rons, suggesting full-effector tau antibodies can
induce indirect toxicity via microglia. We conclude
that effector function is not required for efficacy,
and effectorless tau antibodiesmay represent a safer
approach to targeting tau.INTRODUCTION
Alzheimer’s disease (AD) pathology is characterized by amyloid
plaques, neurofibrillary tangles (NFTs), extensive neuroinflam-
mation, and neuronal cell death (Glass et al., 2010; Skovronsky
et al., 2006). Tau, a cytosolic solublemicrotubule-binding protein
that is intrinsically unstructured, is the primary constituent of
NFTs, where it is found to be hyperphosphorylated and aggre-1690 Cell Reports 16, 1690–1700, August 9, 2016 ª 2016 The Author
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is the hallmark of several neurodegenerative diseases collec-
tively termed tauopathies, which include AD, progressive supra-
nuclear palsy (PSP), frontotemporal dementia (FTD), cortico-
basal degeneration (CBD), Pick’s disease, and others, and the
causal significance of tau in neurodegeneration is apparent
from disease-causing autosomal-dominant tau mutations (Goe-
dert et al., 2012).
Multiple lines of evidence suggest that tau, while typically
thought of as an intracellular cytosolic protein, can also be
found extracellularly. Tau has been shown to be released
by cultured cells via an unconventional mechanism (Chai
et al., 2012), extracellular tau has been measured directly in
the interstitial fluid in mice (Yamada et al., 2011), and tau is
present in human cerebrospinal fluid (CSF), where its concen-
tration is elevated in AD patients (Shaw et al., 2009). The tau-
spread hypothesis stipulates that pathological tau can spread
from cell to cell via the extracellular environment, thereby
propagating disease progression. In support of this idea,
the spread of tau pathology has been demonstrated in
cultured cells (Kfoury et al., 2012), animal models (de Calig-
non et al., 2012; Iba et al., 2013; Liu et al., 2012), and AD pa-
tients as disease progresses, correlating with cognitive
decline (Braak and Braak, 1991, 1995). Approaches utilizing
antibodies to target tau have been successful in reducing pa-
thology in tau transgenic mouse models (Boutajangout et al.,
2011; Chai et al., 2011; d’Abramo et al., 2013; Yanamandra
et al., 2013); however, the mechanisms and possible liabilities
of therapeutic approaches using tau antibodies remain poorly
understood.
The therapeutic promise of immunotherapy needs to be
balanced by potential liabilities associated with immune modu-
lation, particularly in the nervous system (Yu and Watts, 2013).
This is apparent from cases where amyloid-b-targeting anti-
bodies have led to vasogenic edema (ARIA-E; amyloid-related
imaging abnormalities) (Ostrowitzki et al., 2012; Sperling
et al., 2012), a liability that can be mitigated by reducing(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Age-Dependent Spread and
Accumulation of Phosphorylated Tau Pa-
thology in the Hippocampus of Tau P301L-
Tg Mice
(A) Representative images of P301L-Tg mouse
hippocampi of the designated ages stained for
S409-phosphorylated tau (PG5 antibody, top
panels), T212/S214-phosphorylated tau (pT212/
pS214 antibody, middle panels), and total human
tau (HT7 antibody, bottom panels). Scale bar,
500 mm.
(B) Quantification of the area of hippocampal
pS409-Tau pathology in Tau P301L-Tg (Tg;
red), wild-type littermates (WT; green) and tau
knockout (KO; blue) mice. Each point is the
average percent area stained for three sections
from a single animal.
(C) Western blot of brain lysates showed an age-
dependent increase in pTau in P301L-Tg mice.
Brain lysates from mice of the indicated geno-
types and ages were probed for pS202pT205,
pT212pS214, human tau-specific (HT7), and
b-actin. Paired arrows indicate the molecular
weight of human P301L Tau (60–70 kDa), and the
upper arrow of each pair corresponds to hyper-
phosphorylated Tau.antibody effector function (Adolfsson et al., 2012). The state of
neuroinflammation in AD (reviewed in Wyss-Coray and Rogers,
2012) further exemplifies the need to assess the potential
impact of antibody treatment on inflammatory responses, and
especially the role effector function may play in these re-
sponses, as well as in efficacy.
Effector function, an intrinsic property of an antibody that
drives phagocytic and proinflammatory responses, is mediated
by antibody interactions with immune cells via Fcg receptors
(FcgRs) and complement, and these interactions can be modu-
lated by mutations in the immunoglobulin G (IgG) Fc region
(Leabman et al., 2013). The question of whether effective tau im-
munotherapeutics require effector function has not previously
been investigated. Indeed, it may be that antibody binding of
tau is sufficient to prevent it from spreading, without the addi-
tional requirement for effector function, thus avoiding potential
pro-inflammatory side effects.
In this study, utilizing phospho-serine-409 tau antibodies with
effector variants, we explored the mechanisms underlying tau
antibody efficacy, including whether antibody effector function
is required to reduce accumulation of tau pathology in vivo.
We further investigated the cellular implications of treatment
with effector function variants of anti-tau on cultured neurons
and microglia. We show that effector function is not required
for efficacy in vivo and that, although full effector function anti-
tau promotes microglial uptake of extracellular tau, it also elicits
microglial release of proinflammatory cytokines that could have
deleterious effects on neurons. Our results suggest that attenu-
ation of antibody effector function may offer a safer route for tar-
geting tau with antibodies and shed light on the mechanism of
action of tau antibodies.RESULTS
Age-Dependent Accumulation of Phospho-tau
Pathology in Tau P301L-Tg Mice
We first characterized the accumulation of tau pathology by
immunohistochemistry (IHC) and biochemistry in Tau P301L-
Tg mice (Go¨tz et al., 2001), a tauopathy mouse model
that expresses human tau harboring a mutation that causes
frontotemporal dementia. Hippocampal phospho-tau pathol-
ogy increases with age in this model, beginning in the
subiculum and CA1 regions at 2 months of age and pro-
gressing toward CA2/3 and reaching a maximum burden
at 12 months (Figures 1A and 1B). Western blots of brain
lysates confirmed age-dependent increases in hyperphos-
phorylated tau (Figure 1C). Using both methods, we de-
tected age-related increases in a range of phospho-tau
epitopes, including pS202pT205, pT212pS214, and pS409
(Figures 1A and 1C).
Generation and Characterization of Anti-pS409-Tau Full
Effector and Effectorless Antibodies
Phosphorylated serine-409 is a phospho-tau epitope that has
been reported to appear early in tangle formation and persist
in NFTs (Kimura et al., 1996). We generated a murine therapeutic
antibody targeting pS409-Tau, confirming its phospho-epitope
specificity and its reactivity to pathological human tau by ELISA,
western blot, and IHC (Figures 2A–2D and S1). An effectorless
version of the full effector recombinant murine IgG2a antibody
was engineered by introducing the D265A and N297G (DANG)
mutations in the Fc region, which, combined, abolish binding
to FcgRs (Couch et al., 2013).Cell Reports 16, 1690–1700, August 9, 2016 1691
Figure 2. A Murine Therapeutic Antibody Specific to S409-Phosphorylated Tau Reacts with Pathological Tau from Human AD Patients
(A) Selectivity of the antibody to phospho-S409 tau was confirmed by ELISA against phospho- and non-phospho-peptides (top) as well as recombinant human
tau nonphosphorylated or phosphorylated in vitro with PKA (bottom).
(B) Western blot using full-length Tau protein phosphorylated with PKA at 2,088 U/ml (Low PKA) or 12,525 U/ml (High PKA) or unphosphorylated (No PKA). pS409
antibody specifically detected the phosphorylated tau (red arrow). Total tau bands (pink arrow) were visualized with a pan-tau antibody (Tau-5).
(C) Cortical brain sections from Alzheimer patient and healthy control stained with anti-pS409 antibody by immunohistochemistry. Scale bars, 50 mm.
(D) Detection of pS409-Tau in human brain S1 homogenates using biotinylated the pS409-Tau antibody. A significant difference (p < 0.0001, Mann-Whitney test)
was observed between AD and control brains.Effector Function Is Not Required for Targeting Spread
of Tau Pathology In Vivo
Tau P301L-Tg mice were injected intraperitoneally once weekly
for 3 months starting at 3 months of age with either the full
effector (WT) or effectorless (DANG) pS409-Tau antibodies or a
control IgG2a antibody. Plasma and perfused brains were har-
vested for analyses 24 hr after the last dose, antibody concentra-
tions were measured (Figure S2), and right hemispheres were
processed for histopathology. A significant reduction in hippo-
campal tau pathology was observed in mice treated with both
WT and DANG pS409-Tau antibodies (Figures 3A and 3B). To
biochemically assess the effect of antibody treatment on tau pa-
thology, hippocampi from the left hemispheres were homoge-
nized and fractionated for western blot analysis of insoluble
phospho-tau. Both WT and DANG anti-pS409-Tau variants
significantly lowered insoluble levels of phospho-tau, with no
significant difference between the antibodies (Figures 3C–3E).
Importantly, 3-month dosing of older animals starting at
11.5 months of age, when pathology is already maximally estab-
lished (see Figure 1B) did not reduce hippocampal tau pathology
(Figure S3). Taken together, these results suggest that in vivo,
tau antibodies do not clear existing intra-neuronal pathology
but rather slow down the spread of pathology in earlier stages
of propagation. Because in vivo efficacy is independent of anti-
body effector function status, the data further suggest that tau
antibodies can be efficacious without binding to FcgRs.
pS409-Tau Antibodies Protect Cultured Neurons from
Tau-Induced Toxicity Independent of Effector Function
Status
To gain mechanistic insight into anti-tau function, we tested the
capacity of our tau antibodies to protect cultured neurons from1692 Cell Reports 16, 1690–1700, August 9, 2016tau-induced toxicity. We phosphorylated recombinant human
tau in vitro with protein kinase A (PKA), which phosphorylates
tau on S409 (Jicha et al., 1999), and oligomerized the phos-
pho-tau protein (Figure S4).When added to themedia of cultured
mouse hippocampal neurons, oligo-pTau caused toxicity in a
concentration-dependent manner (Figures S5A and S5B), visu-
alized as fragmentation of MAP2 staining along neurites. Oligo-
meric tau that was not PKA phosphorylated also induced
neuronal toxicity, comparable to oligo-pTau (Figure S5C). Mono-
meric tau, on the other hand, did not cause any noticeable
toxicity to cultured neurons, even at high concentrations (Fig-
ure S5C). For subsequent experiments, a high oligo-pTau con-
centration (500 nM) was used to ensure robust toxicity. We
treated cultured neurons with vehicle control, oligo-pTau, or
oligo-pTau plus equimolar concentration of anti-pS409-Tau
WT, anti-pS409-Tau DANG, or IgG2a-control. Automated quan-
tification of MAP2 fragmentation showed that oligo-pTau-
induced toxicity is blocked in the presence of either tau antibody
variant, irrespective of effector function status (Figures 4A and
4D). In cultures treated with oligo-pTau or oligo-pTau plus
IgG2a-control, tau staining was observed in both neurons as
well as non-neuronal cells (Figure 4B). In contrast, neurons that
were treated with oligo-pTau together with tau antibodies
showed minimal tau staining in neurons, seen as lack of staining
overlapping with MAP2-positive neurons; however, there ap-
peared to be some tau staining in non-neuronal cells. Anti-Tau
or control antibodies were detected in non-neuronal cells but
not in neurons (Figure 4C). Both WT and DANG antibodies
showed comparable dose-dependent protection of cultured
neurons exposed to 500 nM oligo-pTau (Figures S5D and S5E).
Our data indicate that tau antibodies may prevent internaliza-
tion of extracellular tau by neurons, although some published
Figure 3. Reduction in Hippocampal Tau
Pathology in P301L-Tg Mice following 3
Months Weekly Intraperitoneal Dosing with
Anti-pS409
3-month-old P301L-Tg mice and WT controls
were dosed weekly with anti-pS409 tau antibodies
for 3 months.
(A) Significant reduction in pS409 tau staining in
P301L-Tg mice dosed with the full effector
pS409 WT antibody was observed in all dose
groups (ANOVA for dose level, p = 0.008;
comparisons to 30 mg/kg control IgG group by
two-tailed Student’s t test; *p = 0.0281, **p =
0.0091, and ***p = 0.0002). Representative im-
ages of mice treated with 30 mg/kg control
antibody (above) and 30 mg/kg anti-pS409 WT
antibody (below), corresponding to individuals
as indicated.
(B) Significant reduction of pS409 tau staining in
P301L-Tg mice dosed with the effectorless pS409
DANG antibody in both dose groups (ANOVA for
dose level, p = 0.048; compared to 30 mg/kg
control IgG group; 2-tailed Student’s t test, *p =
0.0395, **p = 0.0083) Representative image of
30 mg/kg anti-pS409 DANG-treated mouse, cor-
responding to the individual mouse data point, as
indicated. p values were calculated by two-tailed
Student’s t test. For ease of comparison, graphs
in (A) and (B) show the same baseline and control-
IgG-treated animals. In (A) and (B), each point
represents an averaged quantification of three or
four sections per animal measured for integrated
signal intensity of pS409 tau within the hippo-
campal ROI. Baseline indicates transgenic mice at
the start of the study (3 months old) that were
never treated. No pS409 tau signal and no anti-
body effect were detected in WT littermate ani-
mals (not depicted).
(C–E) Anti-pS409-Tau reduces accumulation of
insoluble phosphorylated tau in hippocampal ly-
sates of P301L-Tg mice following 3-month weekly
intraperitoneal dosing. Western blot data from
insoluble fractions of hippocampal homogenates
from the same mice treated with 30 mg/kg
antibodies shown in (A) and (B). In (C), lanes
numbered in green indicate samples loaded twice
for gel factor normalization. In (D) and (E), graphs
represent densitometric quantification of normal-
ized band intensities of phospho-tau to b-actin.
Treatment with both full effector function IgG2a
WT and effectorless DANG antibodies resulted in
comparable and significant reduction in phospho-tau (pS202pT205 and pT212pS214) levels in insoluble fractions (P2; see Experimental Procedures).
***p < 0.001, two-tailed Student’s t test versus control IgG treated. Con IgG, control IgG2a antibody; pS409 WT, anti-pS409 IgG2a WT antibody; pS409 DANG,
anti-pS409 IgG2a DANG mutant; numbers (3, 10, and 30) after Con IgG, pS409 WT, and pS409 DANG represent milligrams per kilogram of antibody admin-
istered. See Table S1 for detailed description and count of animals used in this study. AU, arbitrary units. Error bars, SEM; scale bar, 500 mm.studies propose that neurons internalize tau antibodies via
FcgRs (Congdon et al., 2013). We found no evidence of
neuronal expression of FcgRs 1–3 in the online public trans-
criptome database of the wild-type (WT) mouse CNS (http://
web.stanford.edu/group/barres_lab/brain_rnaseq.html) (Zhang
et al., 2014). To address the possibility that under neurodegen-
erative conditions neurons aberrantly express FcgRs, we
sorted neurons and microglia from adult Tau P301L-Tg and
non-transgenic littermates and assessed the expression ofFcgRs 1–3 by qPCR. For both genotypes, we detected RNA
transcripts of FcgRs in microglia but not in neurons (Figure 5A).
Enrichment of neurons and microglia following cell sorting was
confirmed by the selective detection of the cell-specific RNA
transcripts Grin1 and Cx3Cr1, respectively (Figure 5B). We
also stained cultured hippocampal neurons with the anti-FcgR
antibody against CD16/CD32 and detected no signal; however,
microglia added to the neuronal culture showed clear FcgR
staining (Figure 5C). These results suggest that tau antibodiesCell Reports 16, 1690–1700, August 9, 2016 1693
Figure 4. pS409 Tau Antibodies Protect Cultured Hippocampal Neurons from Toxicity Induced by Recombinant Oligomeric Phospho-tau
Independent of Effector Function
(A–C) Primary cultured hippocampal neurons were treated with recombinant human oligomeric phospho-tau (Oligo-pTau) with or without antibodies. Cells were
stained for human tau, MAP2, and murine IgG. MAP2 staining of dendrites (A), human tau (green) and MAP2 staining (B), and mouse IgG (magenta) and MAP2
staining (C) are shown. MAP2 signal in B and C was linearly and uniformly reduced in all images to better present the corresponding human tau or mouse IgG
signal. Arrows indicate neuronal cell bodies that are lacking human-specific tau signal (B) or mouse IgG signal (C). Asterisks indicate human-specific tau (B) or
mouse IgG (C) staining corresponding with MAP2-negative cells (non-neuronal cell types in hippocampal culture). Arrowheads indicate human tau-positive
neuronal cell bodies. Scale bar, 20 mm.
(D) Automated quantification of MAP2 fragmentation.
Error bars represent SEM; *p < 0.05 by two-tailed Student’s t test between indicated conditions; ns, not significant. Control, vehicle-buffer containing arachidonic
acid and heparin; Con IgG, control IgG2a antibody; pS409 WT, anti-pS409 IgG2a WT antibody; pS409 DANG, anti-pS409 IgG2a DANG mutant. n for each
condition is described in Table S2.bind oligo-pTau extracellularly, preventing its uptake by neu-
rons and consequently neutralizing its toxicity.
Effector Function Drives Antibody-Mediated Uptake of
Extracellular Tau and Pro-inflammatory Cytokine
Release by Cultured Microglia
Next, we determined the impact of antibody effector function on
microglial uptake of extracellular tau. Microglia are the resident
phagocytic immune cells of the CNS (Prinz and Priller, 2014),
and our data show that microglia, but not neurons, express
FcgRs. We therefore hypothesized that full effector antibodies
would enhance uptake of extracellular tau via FcgR-mediated
engulfment. Indeed, when oligo-pTau was added to the media
of cultured microglia, it underwent internalization that was
enhanced by anti-pS409-Tau WT, but not by anti-pS409-Tau
DANG or IgG2a-control (Figures 6A and 6C). As expected,
anti-pS409-Tau WT co-localized with oligo-pTau and FcgRs
(Figure 6B), confirming FcgR-mediated uptake of antibody-tau
complexes. In strong support of this finding, we detect only
residual effectorless or IgG2a-control antibodies in microglia,
and these do not localize with tau or FcgRs (Figure 6A).
Microglial engulfment of antibody-antigen complexes can
trigger release of pro-inflammatory cytokines (Hanisch and Ket-
tenmann, 2007; Prinz and Priller, 2014). Given the possible dele-1694 Cell Reports 16, 1690–1700, August 9, 2016terious effects of chronic inflammation on neurons (Glass et al.,
2010), we tested if full effector anti-Tau activates microglia. We
measured interleukin 6 (IL-6), tumor necrosis factor a (TNF-a),
and IL-1b in media collected from cultured primary microglia
treated with different combinations of oligo-pTau and tau anti-
bodies. We observed a significant increase in levels of all three
cytokines upon exposure to oligo-pTau. The addition of anti-
pS409-Tau WT dramatically increased cytokine levels even
further, an increase that was not observed when anti-pS409-
Tau DANG or IgG2a-control antibodies were added (Figures
6D–6F). Anti-pS409-tau WT alone had no effect on cytokine
levels in the absence of oligo-pTau. These results show that
effector function in the presence of target-bound anti-tau stimu-
lates cytokine release. This cytokine release raises concern for
possible deleterious effects in the CNS, reinforcing the rationale
for mechanistic investigation of the role of effector function in
efficacy and safety.
Only Effectorless, but Not Full Effector, Anti-pS409-Tau
Protects Neurons from Oligo-pTau-Induced Toxicity in
Neuron-Microglia Co-cultures
To directly test whether enhanced microglial activation by full
effector anti-Tau could be deleterious to neurons, we generated
neuron-microglia co-cultures and treated them with oligo-pTau
Figure 5. FcgReceptors Are Not Detectable
in Neurons from Non-Tg or Tau P301L-Tg
Hippocampi or in Cultured Hippocampal
Neurons
(A) Fluidigm qPCR measurement of FcgR1 (top),
FcgR2b (middle), and FcgR3 (bottom) expression
levels in microglia and neurons purified and sorted
by FACS from non-Tg and Tau P301L-Tg mouse
hippocampi. No FcgR-expression was detected in
neurons.
(B) Enrichment of specific cell types after FACS
purification used in (A) was validated bymeasuring
mRNA levels of the cell-type-specific genes Grin1
(neuron-specific, top) and Cx3Cr1 (microglia-
specific, bottom) by Fluidigm qPCR analysis.
(C) 19 DIV embryonic hippocampal culture was
fixed and stained for Iba-1 to detect microglia, with
CD16/CD32 to detect FcgRs and MAP2 to visu-
alize neurons. No FcgR staining was detected in
neurons. However, primary-cultured microglia
added to the hippocampal culture stained positive
for CD16/CD32, confirming that FcgRs are ex-
pressed in microglia.
Scale bars, 20 mm. Error bars represent SD.and antibodies. In the absence of microglia, both WT
and DANG anti-pS409-Tau antibodies prevented oligo-pTau-
mediated neuronal toxicity (Figures 7A, top row, 7B, and 4A).
However, in the presence of microglia, anti-pS409-Tau WT
was no longer protective, as evidenced by severe neuronal frag-
mentation. In contrast, the effectorless anti-pS409-Tau DANG
remained protective (Figures 7A and 7B). Microglial uptake of
oligo-pTau in the co-culture was strongly enhanced by anti-
pS409-Tau WT, but not by anti-pS409-Tau DANG or IgG2a con-
trol (Figure 7C). These data suggest that the protective effect of
anti-tau in blocking oligo-pTau-induced toxicity is lost due to mi-
croglial activation by full effector function anti-tau. The protective
effect is retained, even in the presence of microglia, when
effector function is removed. An effectorless tau antibody can
therefore block spreading of tau pathology in vivo and protect
neurons from direct tau-induced toxicity without activating mi-
croglia in vitro, properties that may be of significant importance
for both safety and efficacy in the already inflamed environment
of a degenerating AD brain.
DISCUSSION
Immunotherapy, particularly passive immunization, is a prom-
ising approach for disease-modifying treatments for Alzheimer’sCell Redisease, based on extensive preclinical
data for anti-amyloid and anti-tau, and
emerging clinical data for anti-amyloids
(Golde, 2014). Trials with amyloid-b-
targeting antibodies have shown both
the promise and potential risks of pas-
sive immunization. Notably, anti-amyloid
therapies have been associated with
ARIA only if the antibody has full effector
function and binds oligomeric or fibrillar
amyloid. Therefore, whether effector function is required for ef-
ficacy becomes a critical question when designing therapeutic
antibodies. We show that a full effector anti-tau antibody en-
hances microglial uptake of extracellular tau in primary cultured
microglia. These data agree with two recently published works
showing that tau antibodies can promote microglial uptake
and clearance of tau (Funk et al., 2015; Luo et al., 2015) and
are consistent with the expression of FcgRs by microglia. In
our study, we further investigated how this microglial uptake af-
fects inflammatory responses and neuronal health. Importantly,
we examined the role of antibody effector function in deter-
mining efficacy, both in vivo and in neuronal cultures, and
show that effector function is not required for reducing accumu-
lation of tau pathology in transgenic mice or for protection of
cultured neurons from tau-mediated toxicity. Moreover, in
neuron-microglia co-cultures exposed to extracellular toxic
tau, only the effectorless anti-tau was protective, suggesting
that while the full effector antibody enhances microglial uptake
of tau, there could be a net negative impact of the antibody on
adjacent neurons via activation of microglia. Based on our re-
sults, we propose that the primary protective mechanism of
tau antibodies is the actual binding to extracellular tau, which
prevents its uptake by neurons. This binding does not require
effector function, since it does not involve the antibody Fcports 16, 1690–1700, August 9, 2016 1695
Figure 6. Effector Function Determines Antibody-Mediated Uptake of Recombinant Oligomeric Phospho-tau and Pro-inflammatory Cyto-
kine Release by Cultured Microglia
Primary cultured microglia were incubated with oligomeric phospho-tau (Oligo-pTau) with and without antibodies.
(A)Microgliawere incubated as indicatedand imaged for tau (green),murine IgG (blue), andeither Iba-1 (not depicted) orCD16/CD32 (red).Representative images of
each condition are shown. Baseline oligo-pTau uptake bymicroglia is enhanced bypS409WT, but notDANG, antibody, andonly Tau taken up in presence of pS409
WT antibody co-localizes with muring IgG (mIgG) and FcgRs, suggesting FcgR-mediated uptake for pS409 WT antibody-Tau complexes only. Scale bar, 5 mm.
(B) High-magnification images of tau, CD16/CD32, and murine IgG in cells treated with oligo-pTau and pS409 WT. Scale bar, 5 mm.
(C) Quantification of tau immunoreactivity shows uptake of oligomeric tau by microglia is enhanced only by the full effector tau antibody. All values were
normalized relative to Oligo-pTau+ConIgG. Error bars represent SEM. ***p < 0.001.
(D–F) Microglia were incubated at indicated conditions for 24 hr, and culturemedia were collected tomeasure IL-6 (D), TNF-a (E), and IL-1b (F) by ELISA. All values
were normalized relative to Oligo-pTau+ConIgG. Error bars represent SEM. *p < 0.05.
n for each condition is indicated in Table S2.
p values by two-tailed Student’s t test. Oligo-pTau, oligomeric phospho-tau; Control, vehicle-buffer containing arachidonic acid and heparin; Con IgG, control
IgG2a antibody; pS409 WT, anti-pS409 IgG2a WT antibody; pS409 DANG, anti-pS409 IgG2a DANG mutant.region. The antibody effector function status, however, may
determine the downstream mechanisms of clearance after the
binding of extracellular tau. Full effector antibodies promote
FcgR-mediated uptake and clearance of tau by microglia.
We show that this can consequently induce inflammatory re-
sponses in cultured microglia. The effectorless antibody, on
the other hand, does not promote microglia-mediated uptake
and therefore does not elicit microglial activation.
Our results suggest that tau antibodies do not target intracel-
lular tau pathology. In vivo, we show that tau antibodies can slow
the accumulation of tau pathology when it is still building up and
spreading, but not at an older age when pathology has pla-
teaued. If antibodies could target intracellular tau, we would
expect to see clearance of existing pathology in treated older
mice as well. A mechanism of action where neuronal FcgRs
mediate antibody uptake by neurons, followed by engagement1696 Cell Reports 16, 1690–1700, August 9, 2016of intracellular tau tangles by the internalized antibody, has
been previously proposed (Congdon et al., 2013; Gu et al.,
2013). Possible reasons for the discrepancy between these
studies and our work could be that in these published studies
antibodies were applied ex vivo to sections of mouse brains,
where the mechanical damage to cells and membranes during
sectioning inevitably exposes intracellular pathology to extracel-
lularly applied antibodies. Our results are based on efficacy
studies in vivo with peripheral administration of the antibodies,
an experimental paradigm that better models the treatment pa-
tients would receive in a clinical setting. The proposed mecha-
nism of intracellular tau clearance by antibodies is based on an
observation by IHC that neurons express FcgRs. However,
non-specific signal is always a risk with this technique, especially
when the antibody specificity has not been validated by lack of
signal in knockout animal tissue. To address the questions of
Figure 7. Only Effectorless, but Not Full
Effector, Anti-pS409-Tau Protects Neu-
rons from Oligo-pTau-Induced Toxicity in
Neuron-Microglia Co-cultures
(A) Representative images of dendrites of neurons
visualized by MAP2 staining (white) and microglia
visualized by Iba-1 staining (green).
(B) Automated quantification of MAP2 fragmen-
tation. Error bars represent SEM; *p < 0.05, **p <
0.01; two-tailed Student’s t test. n for each con-
dition is indicated in Table S2.
(C) Representative images of microglia (Iba-1) and
oligo-phospho tau from each condition. Uptake of
oligo-pTau by microglia is increased in the pres-
ence of anti-pS409 WT, but not DANG.
Scale bars, 20 mm. Control, vehicle-buffer con-
taining arachidonic acid and heparin; Con IgG,
control IgG2a antibody; pS409 WT, anti-pS409
IgG2a WT antibody; pS409 DANG, anti-pS409
IgG2a DANG mutant.FcgR expression in neurons directly, we sorted neurons and mi-
croglia fromWT and transgenic animals and found no detectable
levels of mRNA to FcgRs in neurons. These results are in agree-
ment with the online public transcriptome database of the WT
mouse CNS (Zhang et al., 2014).
Anti-tau antibodies are less likely to cause vasogenic edema
than amyloid-b-targeting antibodies given that NFTs are not
associated with vasculature. A potential concern, however,
arises from the inflammatory state of the brain in AD. It is not
known if treatment with full effector anti-tau would further aggra-
vate neuroinflammation in the diseased brain in a way that would
offset the desired treatment effect of capturing and clearing
extracellular tau.While providing an excellentmodel for accumu-
lation of tau pathology, Tau P301L-Tg mice unfortunately do not
recapitulate the widespread chronic neuroinflammation charac-
teristic of Alzheimer’s brains (Figure S6), which prevents us fromCell Retesting our cell-based findings in vivo.
Therefore, the in vitro risk we identify
here may best predict potential adverse
effects of full effector anti-tau antibodies
in a brain with chronic inflammation.
Importantly, amyloid-related imaging ab-
normalities showing vasogenic edema
(ARIA-E) (Sperling et al., 2012) were not
initially predicted in preclinical animal
studies, yet they are a clear and present
source of concern in currently ongoing
anti-amyloid clinical trials in AD patients.
In summary,weshow that effector func-
tion in anti-tau is not required for efficacy
in vivo. Furthermore, both full effector-
positive and effectorless anti-tau reduce
the toxicity induced by oligo-pTau in pri-
mary neuron cultures. However, only full
effector anti-tau drive microglial engulf-
ment of tau, resulting in robust cytokine
release, which is potentially deleterious
to neurons. Indeed, we observed that in neuron-microglia co-cul-
tures, full effector anti-tau inducesneuronal toxicitywhile effector-
less anti-tau remains protective against oligo-pTau-induced
toxicity.
These results offer important preclinical mechanistic insights
to anti-tau therapy, thus providing potential translational consid-
erations when designing anti-tau therapies for clinical studies.
Our findings may also be broadly applicable to antibody ap-
proaches for treating neurodegenerative diseases beyond tau.
EXPERIMENTAL PROCEDURES
Mice
Transgenic mice expressing human Tau P301L under the Thy1 promoter (Tau
P301L-Tg) were previously described (Go¨tz et al., 2001) and were maintained
on a C57BL/6N (Charles River Laboratories) background. The protocols for
in vivo mouse experiments were approved by the Genentech Institutionalports 16, 1690–1700, August 9, 2016 1697
Animal Care and Use Committee. All work was conducted according to NIH
guidelines for the humane care and treatment of laboratory animals.
Generation of Anti-Tau-pS409 Antibody
Anti-pS409-Tau was generated by vaccinating WT C57BL/6 mice with a
liposomal SupraAntigen vaccine (Muhs et al., 2007) modified to contain a pal-
mitoylated peptide carrying the pS404 and pS409 tau phospho-epitopes.
Splenocytes were fused with SP2/O-Ag14myeloma cells, and the hybridoma
expressing the antibody was isolated and expanded by limiting dilution. The
specificity of the antibody to the Tau-pS409 epitope was verified with ELISA
assays using multiple phospho- and nonphospho-peptides (Anawa Trading
SA) and full-length human tau (tau-441; SignalChem) phosphorylated on
the serine 409 site by a recombinant protein kinase A (PKA) catalytic sub-
unit (New England Biolabs) at 12,525 U/ml. Further characterization
was performed by western blot using full-length recombinant tau protein,
unphosphorylated or phosphorylated with PKA at 2,088 U/ml (low PKA) or
12,525 U/ml (high PKA) (Figure 2). Anti-pS409-Tau was sequenced and var-
iable regions cloned into WT and DANG murine IgG2a and murine kappa
light-chain expression vectors.
Anti-pS409-Tau IgG2a WT and DANG were expressed in Chinese hamster
ovary (CHO) cell line and purified by Protein A affinity chromatography,
followed by size-exclusion chromatography to remove aggregate. Purity
(> 95%) was verified by SDS-PAGE gel and size exclusion chromatography
with multi-angle light scattering (SEC-MALLS). Identity of the antibodies
was confirmed by mass spectroscopy. The endotoxin level was less than
0.5 EU/mg as measured by the limulus amebocyte lysate (LAL) assay.
Immunohistochemistry of Human Cortical Brain Sections
IHC was performed on 4um thick formalin-fixed, paraffin-embedded tissue
sections mounted on glass slides. All IHC steps were carried out on the
Ventana Discovery XT automated platform (Ventana Medical Systems). Sec-
tionswere treatedwith VentanaProtease 2 for 8min (VentanaMedical Systems)
and then incubated in pS409 antibody at a working concentration of 0.05 mg/ml
for 60 min at 37C. Specifically bound primary antibody was detected by the
OmniMap anti-mouse HRP detection for 16 min, followed by ChromoMap
DAB (VentanaMedical Systems). The sectionswere counterstainedwithHema-
toxylin II (Ventana Medical Systems), dehydrated, and coverslipped.
AlphaLISA of Human Cortical Brain Lysates
Details are provided in the Supplemental Experimental Procedures.
Antibody Treatment and Dosing
Tau P301L-Tg andWT littermate mice were assigned to treatment groups and
dosed once weekly intraperitoneally (i.p.) with IgG2a-control (anti-ragweed) at
30 mg/kg; anti-pS409-Tau WT IgG2a at 3, 10, or 30 mg/kg; or anti-pS409-Tau
DANG IgG2a at 3 or 30 mg/kg. All antibody dosing solutions were prepared in
10mMhistidine (pH 5.8), 6% sucrose, and 0.02% Tween 20 at a concentration
of 10 mg/ml. Treatment started at 13 weeks of age. The groups in the in vivo
study were balanced for sex and litter and staggered into four cohorts. In addi-
tion, three TauP301L-Tg mice were harvested at age 3 months without under-
going any treatment in order to determine the baseline level of pathology at the
time of treatment initiation. Refer to Table S1 for detailed description of total n
by treatment, genotype, and sex.
Mouse Tissue Harvest
Mice were anesthetized with 2.5% tribromoethanol (0.5 ml per 25 g body
weight) and transcardially perfused with PBS. Brains were harvested and bi-
sected. Right hemispheres were fixed in 4% paraformaldehyde overnight at
4C then transferred to PBS prior to processing for immunohistochemistry.
Left hemispheres were sub-dissected on ice then frozen at 80C for
biochemical analysis. Tail clips were taken from all mice to confirm genotypes.
Cerebella and plasma were harvested and used for antibody exposure anal-
ysis (see the Supplemental Experimental Procedures).
Mouse Brain Section Preparation and Immunohistochemistry
For model characterization (Figures 1A and 1B) and aged in vivo study (Fig-
ure S3), hemibrains were sectioned at 35 mm thickness as free-floating sec-1698 Cell Reports 16, 1690–1700, August 9, 2016tions. For the efficacy study (Figure 3), brains were embedded into a gelatin
matrix using MultiBrain blocks (NeuroScience Associates) and sectioned
sagittally at 25 mm thickness. Each sex was represented on separate blocks,
but within each block, the brain position was randomized relative to genotype
and treatment.
Free-floating sections of individual mouse hemibrains or of MultiBrain
blocks were stained as previously described (Le Pichon et al., 2013) but
with washes in PBS instead of Tris buffered saline and primary antibody in-
cubations at 4C instead of room temperature. Primary antibodies included:
rabbit anti-pTau212/214 (generated in-house; 0.01 mg/ml, Figure S7), mouse
IgG3 antibody PG-5 (Peter Davies, AECOM, 1:300), anti-tau HT7 (MN1000,
Thermo Scientific, 1:1,000), rat anti-CD68 (clone FA-11, MCA1957, Serotec,
1:800). To avoid high background staining, in the case of mouse primary an-
tibodies that were subtype specific, we used the corresponding subtype-
specific secondary antibody (e.g., biotinylated anti-mouse IgG3, Bethyl
A90-111B).
IHC Quantification
Immunohistochemically stained slides were imaged using the Leica SCN400
(Leica Microsystems) whole-slide scanning system at 2003 magnification
with a resolution of 0.5 mm/pixel. Regions of interest (ROIs) were manually
drawn on four matched hippocampal levels per animal, and the amount of
staining in these ROIs was quantified in an automated fashion using the two
endpoints described below. All image analysis was performed blind to geno-
type and treatment groups.
Positive Pixel Area Analysis for Quantitation of IHC Stains
Digital images of antibody-labeled brain sections were analyzed as previously
described (Le Pichon et al., 2013). The percent area stained was calculated by
normalizing the total positive pixels to the total pixel area of the ROI.
Integrated Intensity
Integrated intensity was calculated using the Beer-Lambert law, absorbance =
log(transmitted light intensity/incident light intensity), for the positive pixel
areas only.
Biochemical Characterization of Tau P301L-Tg Mice
Details are provided in the Supplemental Experimental Procedures.
Biochemical Analysis and Quantification of Efficacy Studies
Left hemispheres from Tau-P301L-Tg or WT littermates were subdissected
and hippocampi were homogenized in 200 ml TBS (50 mM Tris [pH 7.4],
150 mM NaCl, 2 mM EGTA, Complete Mini and PhosSTOP) using Tissue-
Lyser. The lysates were centrifuged at 14,000 3 g (12,000 rpm) for
10 min at 10C to separate supernatant (S1) and pellet (P1). S1 was further
centrifuged at 180,000 3 g (55,000 rpm) for 1 hr at 20C. The supernatants
(S2) were carefully removed and the pellets (P2) were resuspended in 50 ml
of 1% sarkosyl-containing TBS and sonicated. Following protein measure-
ment by BCA, P2 lysates were mixed with SDS-PAGE loading buffer and
boiled, and 5 mg (for total tau) or 15 mg (for phospho-tau) protein lysates
were subjected to SDS-PAGE, transfer, and incubation with primary anti-
bodies (anti-tau, A0024, DAKO; AT8, MN1020, Thermo Scientific, and
rabbit polyclonal anti-pT212pS214, described above) at 4C overnight
followed by incubation with fluorescence-conjugated secondary antibodies
(LI-COR). Fluorescence was detected with an Odyssey scanner (LI-COR).
The intensities of bands at the molecular weight of human tau (60–70
KDa), and b-actin bands were measured with the integrated LI-COR anal-
ysis software.
Generation of Recombinant Tau andOligomeric Phosphorylated Tau
Details are provided in the Supplemental Experimental Procedures.
Primary Hippocampal and Microglial Cultures
Details are provided in the Supplemental Experimental Procedures.
Hippocampal-Microglial Co-cultures
Hippocampal-microglial co-cultures were prepared by replating microglia
dissociated from 225-mm2 culture flasks onto 18 days in vitro (DIV) primary
hippocampal neurons in eight-well slide chambers (12,500 microglia and
25,000 neurons per one well). Co-cultures were treated with recombinant tau
and antibodies 4 hr after microglia plating.
In Vitro Treatment with Recombinant Tau and Antibodies
For 18 DIV hippocampal cultures or hippocampal-microglial co-cultures, re-
combinant human oligomeric phospho-tau and antibodies (500 nM each at
1:1 ratio) or controls were pre-incubated in neuron culture medium (condi-
tioned medium from 18 DIV hippocampal culture:fresh NbActiv4 at 1:1) for
1 hr at 37C before they were added to the cells. Cells were incubated with
the tau-antibody mix or control in the media for 72 hr (hippocampal cultures)
or 48 hr (hippocampal-microglial co-cultures). Cells were washed with PBS
three times before fixation.
For microglia cultures, recombinant human oligomeric phospho-tau and
antibodies or controls were pre-incubated at 500 nM each (immunocyto-
chemistry/imaging) or 250 nM each (cytokine assay) in low-glucose DMEM
in the absence of serum for 1 hr at 37C prior to the addition to the cells.
For immunocytochemistry and imaging, cells were incubated with the tau-
antibody mix or controls for 10 min and washed three times with PBS before
fixation. For cytokine assay, cells were incubated with the tau-antibody mix
or control for 24 hr and medium of each well was collected for cytokine
assay.
Immunocytochemistry
Details are provided in the Supplemental Experimental Procedures.
Confocal Imaging and Quantification
Confocal fluorescent imaging was performed with a LSM780 (Carl Zeiss) using
Zen 2010 software (Carl Zeiss). For imaging of hippocampal cultures and hip-
pocampal-microglial co-cultures, 5 z-stack images at 0.98-mm intervals were
collected using a Plan-Apochromat 203/0.8 M27 objective lens. For theMAP2
fragmentation assay, a maximum intensity z projection was created for the im-
age stack and analyzed using Metamorph (Molecular Devices). A median filter
and nearest-neighbor deconvolution were used for noise reduction. Neurite
and cell body lengths were analyzed using the neurite outgrowth module
followed by morphological processing. Fragments less than 15 pixels
(6.225 mm) were normalized to total signal length to obtain a measure of
MAP2 fragmentation.
Microglia were imaged with an a-Plan-Apochromat 1003/1.46 M27
objective. Quantification of recombinant tau uptake in the cells was per-
formed with ImageJ (1.43u, 64-bit, NIH). ROIs of cell area were drawn
manually using Iba-1 signal as a reference. Area and integrated intensity
of tau immunoreactivity of ROIs were measured to obtain tau immunoreac-
tivity normalized to area. All analyses were performed blinded to experi-
mental conditions.
Sorting of Mouse Brain Cells and qPCR
For flow cytometry sorting (fluorescence-activated cell sorting [FACS]) of
adult mouse hippocampi (5–10 months old), both hippocampi per (n = 9
Tau-P301L-Tg, n = 7 non-Tg) were dissected and dissociated in 1.5 ml Ac-
cutase (#SCr005, Millipore) for 20 min at 4C. The tissues were triturated to
single cell suspension in Hibernate-A LF (BrainBits, LLC), passed through a
Percoll gradient, resuspended, fixed in ethanol, and labeled with primary
antibodies: NeuN-488 (MAB377X, 1:1,000, Millipore) and CD11b-APC
(551282, 1:250, BD Biosciences) for 30 min at 4C. DAPI was added to
gate on single cells. The cell-specific subtypes (including ‘‘presort,’’ defined
as DAPI+ cells collected before sorting into the cell-type specific fluores-
cent gates) were isolated by FACS and collected for qPCR analysis by Flu-
idigm. Expression levels of individual genes assayed were normalized to the
geometric mean of 3 stably expressed genes (ACTB, GAPDH, and HPRT)
for each sample (DCt). Negative DCts are plotted. Enrichment of each cell
type by FACS was validated by qPCR of cell-type-specific markers (Fig-
ure 5B). Because there were no sex effects or age effects observed with
qPCR results, sex and age were pooled in the presented data (Figures 5A
and 5B).
Cytokine ELISA
Details are provided in the Supplemental Experimental Procedures.Statistical Analysis
All data collected from mouse studies, including immunohistochemistry and
western blotting, were plotted and analyzed using JMP (Version 10.0.2, SAS
Institute). Two-way ANOVA was used to assess dose level effects, calculated
using a whole model regression analysis with sex, dose level, and the interac-
tion of sex and dose level as factors. There was no effect of sex or any inter-
action between sex and dose level in these studies. Two-tailed Student’s
t test was used to compare each of the treatment groups with a single control.
Data from cell culture experiments were plotted and analyzed with Microsoft
Excel 2008 and Prism (version 6.0f, GraphPad). Two-tailed Student’s t test
was used to compare each pair of conditions. For all analyses of in vivo and
in vitro data, error bars represent SEM (except Figure 5, where error bars
represent SD; *p < 0.05, **p < 0.01, and ***p < 0.001).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.06.099.
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